Bangladesh · Delayed Price · Currency is BDT Orion Pharma Statistics
Total Valuation
Orion Pharma has a market cap or net worth of BDT 6.95 billion. The enterprise value is 34.89 billion.
| Market Cap | 6.95B |
| Enterprise Value | 34.89B |
Important Dates
The last earnings date was Thursday, January 29, 2026.
| Earnings Date | Jan 29, 2026 |
| Ex-Dividend Date | Dec 5, 2024 |
Share Statistics
Orion Pharma has 234.00 million shares outstanding.
| Current Share Class | 234.00M |
| Shares Outstanding | 234.00M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.23 |
| PB Ratio | 0.32 |
| P/TBV Ratio | 0.35 |
| P/FCF Ratio | 59.14 |
| P/OCF Ratio | 9.69 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 66.78, with an EV/FCF ratio of 296.89.
| EV / Earnings | -61.28 |
| EV / Sales | 11.19 |
| EV / EBITDA | 66.78 |
| EV / EBIT | n/a |
| EV / FCF | 296.89 |
Financial Position
The company has a current ratio of 2.06, with a Debt / Equity ratio of 1.24.
| Current Ratio | 2.06 |
| Quick Ratio | 1.79 |
| Debt / Equity | 1.24 |
| Debt / EBITDA | 52.00 |
| Debt / FCF | 227.59 |
| Interest Coverage | -0.13 |
Financial Efficiency
Return on equity (ROE) is -2.86% and return on invested capital (ROIC) is -0.12%.
| Return on Equity (ROE) | -2.86% |
| Return on Assets (ROA) | -0.07% |
| Return on Invested Capital (ROIC) | -0.12% |
| Return on Capital Employed (ROCE) | -0.12% |
| Weighted Average Cost of Capital (WACC) | 1.13% |
| Revenue Per Employee | 1.06M |
| Profits Per Employee | -192,745 |
| Employee Count | 2,954 |
| Asset Turnover | 0.06 |
| Inventory Turnover | 1.30 |
Taxes
In the past 12 months, Orion Pharma has paid 94.78 million in taxes.
| Income Tax | 94.78M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -3.57% in the last 52 weeks. The beta is -0.73, so Orion Pharma's price volatility has been lower than the market average.
| Beta (5Y) | -0.73 |
| 52-Week Price Change | -3.57% |
| 50-Day Moving Average | 27.95 |
| 200-Day Moving Average | 30.50 |
| Relative Strength Index (RSI) | 68.67 |
| Average Volume (20 Days) | 242,424 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Orion Pharma had revenue of BDT 3.12 billion and -569.37 million in losses. Loss per share was -2.43.
| Revenue | 3.12B |
| Gross Profit | 1.21B |
| Operating Income | -58.68M |
| Pretax Income | -534.10M |
| Net Income | -569.37M |
| EBITDA | 497.28M |
| EBIT | -58.68M |
| Loss Per Share | -2.43 |
Balance Sheet
The company has 238.18 million in cash and 26.75 billion in debt, with a net cash position of -26.50 billion or -113.23 per share.
| Cash & Cash Equivalents | 238.18M |
| Total Debt | 26.75B |
| Net Cash | -26.50B |
| Net Cash Per Share | -113.23 |
| Equity (Book Value) | 21.51B |
| Book Value Per Share | 85.74 |
| Working Capital | 8.97B |
Cash Flow
In the last 12 months, operating cash flow was 717.15 million and capital expenditures -599.63 million, giving a free cash flow of 117.52 million.
| Operating Cash Flow | 717.15M |
| Capital Expenditures | -599.63M |
| Free Cash Flow | 117.52M |
| FCF Per Share | 0.50 |
Margins
Gross margin is 38.68%, with operating and profit margins of -1.88% and -18.26%.
| Gross Margin | 38.68% |
| Operating Margin | -1.88% |
| Pretax Margin | -17.13% |
| Profit Margin | -18.26% |
| EBITDA Margin | 15.95% |
| EBIT Margin | -1.88% |
| FCF Margin | 3.77% |
Dividends & Yields
This stock pays an annual dividend of 1.00, which amounts to a dividend yield of 3.37%.
| Dividend Per Share | 1.00 |
| Dividend Yield | 3.37% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | 3.37% |
| Earnings Yield | -8.19% |
| FCF Yield | 1.69% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 27, 2013. It was a forward split with a ratio of 1.2.
| Last Split Date | May 27, 2013 |
| Split Type | Forward |
| Split Ratio | 1.2 |
Scores
Orion Pharma has an Altman Z-Score of 0.53 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.53 |
| Piotroski F-Score | 4 |